LifeMD, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Justin Schreiber
- Full Time Employees
- 304
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 236 Fifth Avenue New York City NY United States of America 10001
- IPO Date
- Oct 5, 2021
- CIK
- 0000948320
- Website
- lifemd.com
- Similar Companies
- Business
- LifeMD, Inc. operates as a comprehensive direct-to-patient telehealth enterprise, seamlessly connecting individuals with licensed medical professionals across the United States for a diverse array of health needs. The company provides virtual care spanning primary and urgent care, alongside specialized services in areas such as men's health, women's health, weight management including GLP-1 medications, and dermatology. Its digital ecosystem integrates a robust electronic medical record system, advanced scheduling, customer relationship management, remote diagnostics, and a proprietary cloud pharmacy for prescription fulfillment. Through its specialized brands, LifeMD offers targeted solutions like RexMD for various men's health concerns and Cleared for personalized allergy, asthma, and immunology treatments. The platform further extends to women's health and tele-dermatology, delivering virtual consultations and tailored treatment plans. In a strategic move in November 2025, LifeMD divested its majority interest in WorkSimpli Software, affirming its commitment as a pure-play virtual care and pharmacy provider. LifeMD's revenue streams primarily encompass subscription plans for continuous access to its telehealth services, direct sales of prescription and over-the-counter medications, and fees for individual virtual consultations. The company has recently expanded its affiliated pharmacy to include non-sterile compounding capabilities, enhancing its ability to deliver customized medications efficiently. Furthermore, LifeMD has forged key partnerships, including collaborations with major pharmaceutical companies like Novo Nordisk and Eli Lilly, to offer GLP-1 weight-loss medications to its patients. With a focus on accessibility and affordability, LifeMD continues to broaden its offerings, including the introduction of private health insurance acceptance in 2024. LifeMD, Inc. was initially established in 1994 and maintains its headquarters in New York, New York.
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
LifeMD Appoints Umesh Sripad as Chief Technology Officer
LifeMD to Participate in Upcoming Investor Conferences
LifeMD, Inc. (LFMD) Q1 2026 Earnings Call Transcript
LifeMD to Report First Quarter 2026 Financial Results on May 6
LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD, Inc. (LFMD) Q4 2025 Earnings Call Transcript
LifeMD Reports Fourth Quarter and Full Year 2025 Results
LifeMD to Participate in Two Investor Conferences During March
LifeMD to Report Fourth Quarter 2025 Financial Results on March 9
LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.
LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD (NASDAQ:LFMDP) Trading 0.5% Higher – Time to Buy?
LifeMD, Inc. (LFMD) Q3 2025 Earnings Call Transcript
LifeMD Reports Third Quarter 2025 Results
LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk